

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on June 26th, 2025, regarding the number and election of members of the board of directors.

The nomination committee proposes six members of the board of directors and no deputy members of the board of directors.

The nomination committee proposes re-election of Erika Kjellberg Eriksson, Mario Gualano, Karin Fischer and Jonas Jarvius as members of the board of directors, and election of Johan Bygge and Sebastian Backlund for a term of office until the end of the next annual general meeting. Furthermore, the nomination committee proposes election of Johan Bygge as chairman and re-election of Mario Gualano as vice chairman of the board.

Johan Bygge has a solid background in leading and developing prominent global companies, including CFO at Investor, Asia Head of EQT and senior executives at both Electrolux and Husqvarna. He currently sits on several boards, including: Tredje AP-fonden, Getinge AB (publ), Lantmännen ek för, CapMan Oyj, Scandi Standard AB (publ) and Guard Therapeutics International AB (publ). Johan's expertise in building companies for the long term and developing global market-leading companies makes him an optimal choice for chairman of Q-linea given the commercialization phase the company is in.

Sebastian Backlund is employed by Investment AB Öresund as Investment Manager and is expected to contribute to the work of the board and the company with his strong knowledge in financial and commercial analysis, internal structure and process improvement, capital market as well as M&A experience from his previous employers: MedCap AB (publ) and EY Corporate Finance. Sebastian currently sits on the board of Scandi Standard AB and has also served on the board of Multi-Ply Components. With Sebastian as an addition to the board, Q-linea gains access to additional knowledge and experience that are valuable for the journey towards becoming a profitable growth company.

Information about all the members proposed to Q-linea's board, the nomination committee's reasoned statement regarding the proposal to the board and the nomination committee's complete proposal will be available on the company's website, www.qlinea.com in connection with the issue of the notice to the 2025 annual general meeting, which is expected to take place during the week 21.

The nomination committee has been appointed according to the principles decided by the 2024 annual general meeting and consists of Öystein Engebretsen (Investment AB Öresund), chairman of the nomination committee, Erika Kjellberg Eriksson (Nexttobe AB, chairman of the board) and Ulf Landegren (Landegren Gene Technology AB).

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors